Hepatectomy for HCC vs. Intrahepatic Bile Duct Stones: Are Technical, Anatomical, and Outcome Profiles Different?
|
Tại
khoa Ngoại gan mật tụy, cắt gan là phẫu thuật siêu bự với 2 chỉ định chính là
HCC và sỏi đường mật trong gan kèm hẹp đường mật, teo nhu mô,… Rõ
ràng là khác nhau về mặt chỉ định, nhưng “ Về mặt kỹ thuật, giải phẫu,
các biến chứng và kết cục có khác nhau giữa phẫu thuật cắt gan do HCC và do sỏi
không? |
I.
INDICATIONS AND PATIENT SELECTION: HCC VERSUS IBDS
Indications for Hepatic Resection in
Primary HCC (Non-Cirrhotic) and IBDS
The
indications for hepatic resection in primary hepatocellular carcinoma (HCC) and
intrahepatic bile duct stones (IBDS) without cholangitis or abscess are fundamentally
different, reflecting the distinct pathophysiology and clinical
objectives of each disease. For primary HCC in a non-cirrhotic
liver, hepatic resection is the first-line, potentially curative
treatment. The American Association for the Study of Liver Diseases
(AASLD) and the National Comprehensive Cancer Network (NCCN) both recommend
resection for patients with localized, resectable HCC, preserved liver
function (Child-Pugh A), absence of clinically significant portal hypertension
(CSPH), and an adequate future liver remnant (FLR) of at least 30%
in non-cirrhotic livers and 40% in cirrhotic livers. The absence of
CSPH is defined by the lack of ascites, no varices, and a platelet count
above 100,000/μL. Tumor size is not an absolute contraindication
if the FLR is sufficient, and even large or centrally located tumors may be
resected if technical and functional criteria are met. Multifocal
disease or limited portal vein tumor thrombus may be considered for resection
in high-volume centers after multidisciplinary review, but extrahepatic
metastasis and major vascular invasion remain contraindications
except in highly selected cases.[1-4]
In
contrast, hepatic resection for IBDS is not based on oncologic
principles but on the need for definitive stone clearance and prevention
of complications such as recurrent cholangitis, abscess, or secondary
biliary cirrhosis. Resection is indicated for unilobar or segmental
stone disease associated with irreversible biliary strictures,
parenchymal atrophy, or failed non-surgical therapies (e.g., endoscopic or
percutaneous extraction). The underlying liver is usually non-cirrhotic,
and the main concern is the technical feasibility of complete stone
clearance and the adequacy of the FLR, which is typically less
restrictive than in HCC with cirrhosis. Resection is not indicated
for asymptomatic stones without atrophy or stricture, or when less
invasive methods can achieve clearance.[5-8]
A
summary of the key differences in indications is provided in the following
table, which highlights the quantitative thresholds and clinical criteria for
each disease:
|
Indication Domain |
HCC Without Cirrhosis |
IBDS Without Cholangitis/Abscess |
|
Primary Goal |
Oncologic cure (tumor removal) |
Definitive stone clearance, prevent
complications |
|
Standard Indications |
Localized, resectable HCC; adequate
FLR; good performance |
Diffuse/bilateral stones with
insufficient FLR, absence of atrophy/stricture, successful non-surgical
clearance |
|
Contraindications |
Extrahepatic spread, major vascular
invasion (relative), inadequate FLR, poor performance |
Diffuse/bilateral stones with
insufficient FLR, absence of atrophy/stricture, successful non-surgical
clearance |
|
Surgical Extent |
Determined by tumor location and FLR |
Determined by stone location, atrophy,
stricture |
II.
TECHNICAL AND ANATOMICAL CONSIDERATIONS IN HEPATIC RESECTION
1. Surgical Techniques: Open,
Laparoscopic, Anatomical, and Non-Anatomical Resection
The
technical approach to hepatic resection differs substantially between HCC and IBDS,
both in terms of operative strategy and the choice between open and minimally
invasive surgery (MIS). For HCC, the primary objective is complete
oncologic resection with negative margins, favoring anatomical resection
(AR) when feasible. The AASLD and NCCN now explicitly support MIS
(laparoscopic or robotic) for minor resections in favorable segments,
with major hepatectomy via MIS reserved for high-volume, experienced
centers. MIS is associated with reduced blood loss, lower transfusion
rates, decreased morbidity, and shorter hospital stays, without
compromising oncologic outcomes. For example, a propensity-matched
study found that minimally invasive anatomical resection for HCC resulted in
less blood loss (274 vs. 955 g), lower transfusion rates (17.6% vs. 47.3%), and
reduced major morbidity (4.4% vs. 20.9%) compared to open anatomical resection,
with comparable long-term survival.[9-13]
The
choice between AR and non-anatomical resection (NAR) is nuanced. AR,
which removes the entire portal territory containing the tumor, is
associated with improved disease-free survival (DFS) and lower
ipsilateral recurrence, especially in non-cirrhotic
patients. Randomized controlled trials and meta-analyses show that laparoscopic
anatomical hepatectomy (LAH) yields higher 5-year DFS (33.9% vs. 30.1%,
p=0.009) and lower intrahepatic recurrence compared to laparoscopic
non-anatomical hepatectomy (LNAH), with similar overall survival and
complication rates.[14-17] However, the technical demands of
AR are greater, particularly in the laparoscopic setting, and the benefit over
NAR may be less pronounced in multifocal disease or poor liver function.[18]
For IBDS, the surgical objective is complete stone clearance and resolution of biliary pathology. The extent of resection is dictated by the anatomical distribution of stones and the degree of parenchymal involvement, not by oncologic margins. Anatomical resection is often performed when stones are confined to a specific segment or lobe, but non-anatomical or wedge resection may be appropriate for localized disease or when parenchymal preservation is prioritized. Intraoperative bile duct exploration and clearance are integral, and adjunct techniques such as transhepatic duct lithotomy may be employed for complex cases.[8][19-20] Minimally invasive hepatectomy is increasingly common for IBDS, with meta-analyses showing that laparoscopic approaches are associated with less blood loss, lower complication rates, and faster recovery compared to open surgery, with no increase in residual stones or recurrence.[19][21]
2. Anatomical Challenges and
Planning
Hepatectomy
for HCC requires detailed preoperative imaging to delineate tumor
location, vascular and biliary anatomy, and to estimate FLR. In
non-cirrhotic patients, a minimum FLR of 20% is considered safe, while
in cirrhotics, the threshold rises to 30–40%.[1][3][22-23] Tumors adjacent to major
vascular structures or the hepatic hilum pose additional technical challenges,
requiring meticulous dissection to avoid vascular injury and ensure adequate
margins. In cases of insufficient FLR, preoperative portal vein
embolization (PVE) or staged hepatectomy may be considered.[1][3][22]
For
IBDS, the anatomical challenges are shaped by chronic
inflammatory changes, biliary strictures, segmental ductal dilatation, and
parenchymal atrophy-hypertrophy complex. Segmental bile duct-targeted
liver resection (SBDLR) has been developed to address these challenges,
focusing on complete removal of the affected ducts and parenchyma,
especially for right-sided stones distributed within two segments.[6] Chronic
inflammation and fibrosis often result in dense adhesions, increasing
the risk of intraoperative bleeding and bile duct injury. The risk of
postoperative bile leak is heightened due to extensive ductal dissection
and the presence of multiple small bile ducts in the resection plane.[7-8][20]
III.
PERIOPERATIVE AND LONG-TERM COMPLICATIONS
Quantitative Comparison of
Complication Profiles
The
perioperative and long-term complication profiles of hepatic resection differ
markedly between HCC and IBDS. For HCC, perioperative complications
are primarily influenced by underlying liver function, cirrhosis, portal
hypertension, and the extent of resection. The AASLD reports
postoperative mortality rates below 3% and major morbidity rates of
20–30% at high-volume centers for well-selected patients.[1][3][22] The most common complications
include post-hepatectomy liver failure (PHLF), bleeding, bile
leakage (8–13%), surgical site infections (11–14%), and pulmonary
complications. The risk of PHLF is particularly high in cirrhotic
patients or those with marginal FLR.[1][22][24-27]
In
contrast, hepatic resection for IBDS is performed in patients with benign
biliary disease, often without significant parenchymal dysfunction, but
with a high risk of biliary infection. The perioperative
complication profile is dominated by infectious complications, especially surgical
site infections (SSI) and intra-abdominal abscesses, which are more
frequent than in HCC resections. The incidence of SSI after hepatectomy
for hepatolithiasis is significantly higher (23.8%) compared to HCC (11.3%),
attributed to pre-existing biliary colonization and manipulation of infected
bile ducts.[7-8][28] Bile leakage rates are similar to
those seen in HCC resections, with risk factors including repeat hepatectomy
and prolonged operative time.[24] Operative
morbidity rates for IBDS range from 16–28%, with hospital mortality rates
around 2% in large series.[29-30]
Long-term
complications
in HCC are dominated by tumor recurrence (>70% at 5 years),
chronic liver disease progression, and hepatic decompensation. In
IBDS, the main long-term complications are recurrent stones (8–10%),
cholangitis, and the development of biliary strictures. The risk of
cholangiocarcinoma, while low, is the principal long-term threat to survival in
IBDS.[30-31]
IV.
OUTCOMES, SURVEILLANCE, AND QUALITY OF LIFE
1. Long-Term Survival and Quality of
Life
Long-term
survival after hepatic resection for HCC and IBDS is shaped by disease biology,
recurrence risk, and the potential for malignant transformation. For HCC,
5-year overall survival (OS) rates after resection in well-selected,
non-cirrhotic patients range from 50% to 70%, with 10-year OS rates of 29–50%
in favorable subgroups. However, 5-year recurrence rates exceed
70%, and disease-free survival (DFS) at 5 years is typically 30–45%.[35-40] The
principal determinants of long-term survival are tumor biology (size, number,
vascular invasion), underlying liver function, and the presence of cirrhosis.
For
IBDS, 5-year OS rates after hepatic resection typically range from 80%
to 90%, and 10-year OS rates of 80% have been reported, provided
that complete stone and stricture clearance is achieved and there is no
coexisting malignancy. Stone recurrence rates after resection are low
(8–10%), but the risk of cholangiocarcinoma, while low, is the main
determinant of long-term survival.[5][8][30-31]
Quality
of life (QoL)
after hepatic resection improves over time in both groups, but is generally
higher in patients with benign disease (IBDS) compared to those with
malignant disease (HCC), due to the burden of cancer surveillance and
recurrence risk.[41-44]
2. Postoperative Surveillance and
Management
For
HCC, the AASLD and NCCN recommend indefinite postoperative surveillance
with contrast-enhanced multiphasic CT or MRI every 3–6 months, along
with serum alpha-fetoprotein (AFP) measurement. Early detection of
recurrence facilitates eligibility for potentially curative interventions and
improves overall survival. Adjuvant immune checkpoint inhibitor-based
systemic therapy (atezolizumab plus bevacizumab) is now recommended for
patients at high risk of recurrence, such as those with large tumors,
multiple lesions, vascular invasion, or poor differentiation, based on
recent randomized trials.[1][45] Salvage liver transplantation is
considered for recurrence within Milan criteria, while repeat resection,
ablation, or transarterial chemoembolization (TACE) may be used for
liver-localized recurrence beyond Milan criteria.[1][45-46]
For
IBDS, there are no formalized international guidelines for
postoperative surveillance, but most centers recommend periodic clinical
assessment, liver function tests, and imaging (ultrasound or CT) every 6–12
months to detect recurrent stones, biliary strictures, or
cholangiocarcinoma. The risk of stone recurrence is lower after resection
than after non-surgical management but remains significant, particularly in
patients with residual strictures or incomplete clearance. Infectious
complications, including bile fistula and sepsis, are more common
than in HCC resections, and their risk is increased by prior cholangitis,
bilateral disease, and major hepatectomy.[8][30][47]
V.
LIVER FUNCTION
Impact on Liver Function and
Regeneration
The
impact of hepatic resection on liver function and regeneration is fundamentally
different between HCC and IBDS. In HCC, especially with cirrhosis,
the risk of post-hepatectomy liver failure (PHLF) and impaired
regeneration is high, mandating rigorous preoperative assessment and
patient selection. In non-cirrhotic patients, the liver’s regenerative
capacity is robust, and the risk of PHLF is low, allowing for more extensive
resections. In IBDS, the absence of cirrhosis in most cases allows
for more flexibility in resection, with the main limitation being the
anatomical extent of disease and the need to preserve sufficient parenchyma
to prevent hepatic insufficiency. The ability of the liver to regenerate
after resection in IBDS patients is generally preserved, provided there is no
significant underlying parenchymal disease.[27][56]
INTEGRATED
CLINICAL RECOMMENDATIONS AND PRACTICAL IMPLICATIONS
The
comprehensive comparison of hepatic resection for primary HCC (non-cirrhotic)
and IBDS (without cholangitis or abscess) reveals several actionable,
quantitative, and disease-specific differences that should guide clinical
decision-making:
For
primary HCC, hepatic resection is indicated for localized, resectable tumors in
patients with preserved liver function (Child-Pugh A), no CSPH, and adequate
FLR (≥30% in non-cirrhotic, ≥40% in cirrhotic). Anatomical resection is
favored when feasible, and minimally invasive approaches are preferred for
minor resections. Perioperative management must focus on optimizing liver
function, nutritional status, and minimizing intraoperative blood
loss. Postoperative surveillance with CT or MRI and AFP every 3–6 months
is mandatory, with indefinite duration. Adjuvant immunotherapy
(atezolizumab plus bevacizumab) is now recommended for high-risk
patients. The main risks are PHLF, bleeding, and high recurrence (>70%
at 5 years), necessitating ongoing surveillance and multidisciplinary
management.[1-4][25-27][45-46][56][72-73]
For
IBDS, hepatic resection is reserved for unilobar or segmental disease with
atrophy, stricture, or failed non-surgical therapy. The main goal is
definitive stone clearance and prevention of recurrent infection or
cholangiocarcinoma. Minimally invasive surgery is increasingly preferred,
with anatomical or non-anatomical resection chosen based on stone
distribution. Perioperative management should prioritize infection control
and complete stone clearance. Surveillance is less formalized but should
include imaging every 6–12 months for at least 5 years. The main risks are
infectious complications (SSI, abscess, bile leak), with low rates of PHLF and
stone recurrence (8–10%). Long-term survival is excellent (5-year OS
80–90%), but vigilance for cholangiocarcinoma is warranted.[5-8][19-20][30-31][47]
